Thomas A. MCCOURT - 23 May 2022 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Chief Executive Officer, Director
Signature
/s/ Brian Tessler, Attorney-in-Fact
Issuer symbol
IRWD
Transactions as of
23 May 2022
Net transactions value
-$417,542
Form type
4
Filing time
25 May 2022, 16:05:40 UTC
Previous filing
10 Mar 2022
Next filing
05 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Sale $29,750 -2,587 -0.31% $11.50 832,602 23 May 2022 Direct F1
transaction IRWD Class A Common Stock Sale $251,540 -21,873 -2.6% $11.50 810,729 23 May 2022 Direct F2
transaction IRWD Class A Common Stock Sale $136,252 -11,848 -1.5% $11.50 798,881 23 May 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2019.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 50% of the reporting person's restricted stock units granted on March 26, 2021.
F3 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on June 7, 2021.